Options Whittling Down for Endo Health (ENDP) as CEO Holveck Departs
Tweet Send to a FriendGet Alerts ENDP Hot Sheet
Up)
Trade ENDP Now!
According to Bloomberg, Endo Health Solutions Inc. (Nasdaq: ENDP) has just two solutions left: sell or be sold.
CEO Dave Holveck is resigning his position just a few years after paying $3 billion for American Medical Systems Holdings, causing Endo shares to fall about 27 percent in the process. He is expected to leave the firm in May, or whenever a successor is found.
Endo's largest shareholder, Fidelity Investments, is now pushing for a sale of Company, Bloomberg notes today. Analysts expect that Endo might garner a 26 percent premium on a deal,or $37.50 per share, with Teva Pharma (NYSE: TEVA) and Covidien's (NYSE: COV) spin-off Mallinckrodt two potential acquirers. Valeant Pharma (NYSE: VRX) and Warner Chilcott (Nasdaq: WCRX) may also be potential buyers for Endo's pain drugs unit. Private equity might also get in the mix, though specific firms weren't named.
Fidelity had met with Endo's Board serveal times in 2012, calling for the ousting of Hoveck in the meetings.
Going for 8.6 times trailing 12 month earnings, Endo is nearly the cheapest stock in the specialty pharma sector. The average multiple of Endo's peers is about 27 times with Warner Chilcott trading at just 7.6 times earnings.
Endo didn't comment on the speculation today. Shares are flat in early trading.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
CEO Dave Holveck is resigning his position just a few years after paying $3 billion for American Medical Systems Holdings, causing Endo shares to fall about 27 percent in the process. He is expected to leave the firm in May, or whenever a successor is found.
Endo's largest shareholder, Fidelity Investments, is now pushing for a sale of Company, Bloomberg notes today. Analysts expect that Endo might garner a 26 percent premium on a deal,or $37.50 per share, with Teva Pharma (NYSE: TEVA) and Covidien's (NYSE: COV) spin-off Mallinckrodt two potential acquirers. Valeant Pharma (NYSE: VRX) and Warner Chilcott (Nasdaq: WCRX) may also be potential buyers for Endo's pain drugs unit. Private equity might also get in the mix, though specific firms weren't named.
Fidelity had met with Endo's Board serveal times in 2012, calling for the ousting of Hoveck in the meetings.
Going for 8.6 times trailing 12 month earnings, Endo is nearly the cheapest stock in the specialty pharma sector. The average multiple of Endo's peers is about 27 times with Warner Chilcott trading at just 7.6 times earnings.
Endo didn't comment on the speculation today. Shares are flat in early trading.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: ViroPharma (VPHM) on the Move Following Takeover Chatter - Reuters
- UPDATE: Liberty Global (LBTYA) Interested in Kabel Deutschland - FT
- Five Below (FIVE) Tops Q1 EPS by 1c, Boosts FY13 Outlook
Create E-mail Alert Related Categories
Private Equity, Rumors, Trader TalkRelated Entities
Fidelity Investments, Earnings
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
